HCM
NTLA icon

Highbridge Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Highbridge Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,552
Closed -$149K – 1492
2017
Q1 		$149K Buy
+10,552
New +$142K ﹤0.01% 1351

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Highbridge Capital Management's NTLA Position: Q2 2017 in Review

Highbridge Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2017, closing a stake of 10,552 shares — an estimated $149K sold.

Highbridge Capital Management first reported a position in NTLA in Q1 2017 and held it in 1 quarter. The position peaked at $149K in Q1 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

  • Highbridge Capital Management reported no remaining Intellia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 10,552 Intellia Therapeutics shares in Q2 2017, an estimated $149K.
  • Highbridge Capital Management first reported a position in Intellia Therapeutics in Q1 2017 and held it in 1 quarter.
  • Highbridge Capital Management's Intellia Therapeutics position peaked at $149K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.